LiverSource »  Faculty »  Medical Oncology »  R. Kate Kelley, M.D.
R. Kate Kelley, M.D.

R. Kate Kelley, M.D.

Health Sciences Professor of Clinical Medicine,
Division of Hematology Oncology
Department of Medicine

Contact Information

(415) 353-9888 (appts)
(415) 353-9959 (fax)
1600 Divisadero St.,MZ Bldg A 
San Francisco, CA 94143-1770
katie.kelley@ucsf.edu
Open Popup
  • Harvard College, Boston, MA, B.A., 1993-97, Biochemistry
  • UCLA, M.D., 1998-2002, Medicine
  • UCLA, Intern, 2002-05, Medicine
  • UCLA, Resident, 2005-06, Medicine
  • UCSF, Fellow, 2006-09, Hematology/Oncology
  • American Board of Internal Medicine
  • American Board of Internal Medicine: Medical Oncology - Subspecialty
  • UCSF Helen Diller Family Comprehensive Cancer Center
  • Colon Cancer
  • Hepatocellular Carcinoma (Liver Cancer)
  • Liver Metastases
  • Pancreatic Cancer
  • Rectal Cancer
  • Stomach Cancer
  • Anal Cancer
  • Colorectal Cancer
  • Hepatocellular Carcinoma (Liver Cancer)
  • Liver Metastases
  • Molecular Markers in Solid Tumors
  • Rectal Cancer

Katie Kelly, M.D. is a gastrointestinal oncologist who treats liver cancers such as hepatocellular carcinoma; bile duct cancers such as cholangiocarcinoma; gastric cancer; esophageal cancer; anal, colon and rectal cancer; pancreatic cancer; and gastrointestinal stromal tumors. In her research, her interests include developing clinical trials to identify new treatments for gastrointestinal malignancies, particularly hepatocellular carcinoma, and bile duct cancers.

Kelley graduated from UCLA School of Medicine and completed a residency at UCLA, where she was chief resident in the medicine. She also completed a fellowship in hematology and oncology at UCSF. She received the American Society of Clinical Oncology (ASCO) Young Investigator Award in 2010 and the Gastrointestinal Cancers Symposium ASCO Foundation Merit Award in 2009. Kelley is co-author of a chapter on alimentary cancers in the textbook Current Medical Diagnosis and Treatment.

  1. Wang G, Kelley RK. KRAS mutational analysis for colorectal cancer: Application: Pharmacogenomic. PLoS Curr. 2010.
  2. Kelley RK, Venook AP. Nonadherence to Imatinib during an Economic Downturn. N Engl J Med. 2010 Aug 5; 363(6):596-8.
  3. Ko AH, Venook AP, Bergsland EK, Kelley RK, Korn WM, Dito E, Schillinger B, Scott J, Hwang J, Tempero MA. A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2010 Nov; 66(6):1051-7.
  4. Kelley R, Venook AP. Drug development in advanced colorectal cancer: challenges and opportunities. Curr Oncol Rep. 2009 May; 11(3):175-85.
  5. Kelley RK, Venook AP. Sorafenib in hepatocellular carcinoma: separating the hype from the hope. J Clin Oncol. 2008 Dec 20; 26(36):5845-8.
  6. Kelley RK, Ko AH. Erlotinib in the treatment of advanced pancreatic cancer. Biologics. 2008 Mar; 2(1):83-95.
  7. Rozzelle JE, Dauber DS, Todd S, Kelley R, Craik CS. Macromolecular inhibitors of HIV-1 protease. Characterization of designed heterodimers. J Biol Chem. 2000 Mar 10; 275(10):7080-6.

X